Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy
- Albert Cerussi*,†,
- David Hsiang‡,
- Natasha Shah*,
- Rita Mehta‡,
- Amanda Durkin*,
- John Butler‡, and
- Bruce J. Tromberg*,†
- *Laser Medical and Microbeam Program, Beckman Laser Institute and Medical Clinic, University of California, 1002 Health Sciences Road East, Irvine, CA 92612; and
- ‡Chao Comprehensive Cancer Center, Division of Oncological Surgery, University of California Irvine Medical Center, 101 The City Drive, Orange, CA 92868
-
Communicated by Britton Chance, University of Pennsylvania School of Medicine, Philadelphia, PA, December 21, 2006 (received for review February 9, 2006)
-
Fig. 1.Typical DOS measurement geometry, defining the optical linescan taken over a known tumor location. Complete NIR absorption and scattering spectra were measured at each location.
-
Fig. 2.NIR absorption (Left) and reduced scattering (Right) spectra obtained noninvasively from a 30-mm diameter tumor in the breast of a neoadjuvant chemotherapy subject. (Left) The heightened absorption results from a combination of increased hemoglobin and water relative to normal breast tissue. (Right) The sharp spectral decrease in scattering for tumor tissue is likely due to increases in both cellular density and fibrous tissue in tumor tissue relative to normal breast tissue. Tumor spectra were obtained from the +10-mm position, whereas the normal spectra were taken from the corresponding contralateral position on the normal side. Error bars are the variation from two independent linescans (plotted every 50 nm for clarity).
-
Fig. 3.Linescan results of ctH2O (Upper) and ctHHb (Lower) from the same patient as in Fig. 2. NIR spectra at each linescan location are used to calculate NIR absorber concentrations at each spatial location. Error bars are the variations between two independent linescans.
-
Fig. 4.Plots of changes in tumor ctHHb, ctO2Hb, ctH2O, and stO2 for individual patients, stratified by final pathological response. The plotted value is the average of the DOS parameter within the FWHM. The baseline and ∼1 week points correspond to the measurements taken within 1 week before and within 1 week after the start of therapy, respectively. Responder changes are distinctive from nonresponders. Error bars for the individual measurements are not presented for clarity (5–10%).
Footnotes
- †To whom correspondence may be addressed. E-mail: acerussi{at}uci.edu or bjtrombe{at}uci.edu
- © 2007 by The National Academy of Sciences of the USA
